UroGen Pharma stock fell 1.76 percent on October 7, 2026

Published on 10/08/2026 at 09:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

UroGen Pharma stock was last at USD 40.70 on Nasdaq on October 7, 2026, 19.9 percent below its 52-week high of USD 50.81. Q2 revenue reached USD 72.5 million versus USD 24.2 million a year earlier.

URGN, IL0011407140, Illustration mit AI erstellt.

UroGen Pharma stock (ISIN IL0011407140) fell 1.76 percent on Nasdaq on October 7, 2026. The latest reported quarter showed a sharp commercial expansion for ZUSDURI, the companys bladder-cancer treatment, alongside continued investment in its pipeline.

Revenue more than doubled in Q2

In the Q2 2026 earnings call dated August 5, 2026, Yahoo Finance reported total revenue of USD 72.5 million, compared with USD 24.2 million in Q2 2025. The increase was driven by ZUSDURI, which generated USD 50.4 million in Q2 net product revenue, up 73 percent from Q1 2026.

The same call showed a Q2 net loss of USD 14.4 million, or USD 0.28 per diluted share, compared with a USD 49.9 million loss and USD 1.05 loss per share in Q2 2025. JELMYTO revenue reached USD 22.0 million, while management retained 2026 JELMYTO revenue guidance of USD 97 million to USD 101 million.

Analysts see room above the price

MarketBeat reported on September 17, 2026, that 10 research firms had a Moderate Buy consensus on UroGen Pharma, with eight Buy ratings, one Hold rating and one Sell rating. The average 12-month price objective was USD 52.3750, which is 28.7 percent above the October 7 price of USD 40.70.

UroGen said in its Q2 call that ZUSDURI adoption was expanding across hospital and community practices, with 452 unique prescribers and 1,444 activated accounts as of June 30, 2026. The company also said 204 repeat prescribers represented 45 percent of writers, a commercial metric that links the revenue increase to recurring use rather than a single launch shipment.

Stock remains below its yearly high

UroGen develops sustained-release therapies for urothelial and specialty cancers using its RTGel platform, according to the companys investor-relations profile. The commercial opportunity is therefore tied to both ZUSDURI execution and the progression of UGN-103 and UGN-104.

UroGen Pharma stock was last at USD 40.70 on Nasdaq at 4:00 p.m. ET on October 7, 2026, with a session range of USD 40.64 to USD 41.93. Its 52-week range was USD 15.86 to USD 50.81, and market capitalization stood at USD 2.0 billion.